Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03947632
Other study ID # 2305-Pat-ERC-12
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2013
Est. completion date December 31, 2014

Study information

Verified date May 2019
Source Aga Khan University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The aim of this study was to determine the anthropometric measurements in transfusion-dependent β-thalassemia children in Pakistan. The secondary aim was to correlate serum ferritin with the physical growth


Description:

Material and methods

Setting The study was conducted at the Sections of Hematology and Clinical Chemistry in the Department of Pathology and Laboratory Medicine, Aga Khan University, Karachi, Pakistan during January 2013 to December 2014. Patient recruitment was conducted at a non-profit organization named Fatimid Foundation Karachi (FFK), which provides free of cost blood components to the patients with various blood disorders. There are more than 4000 registered patients of thalassemia and hemophilia at FFK.

Patient selection After informed consent from their parents, 367 pediatric patients (age 5-17 year) with transfusion-dependent β-thalassemia were recruited. All patients were diagnosed based on hemoglobin electrophoresis or high-performance liquid chromatography.

Data collection Detail history was collected by a trained research officer on a predetermined questionnaire. The following information was collected from medical records of the patients: demographics (age, gender, age at the time of diagnosis and at first transfusion), anthropometrics (height and weight), and clinical details (blood transfusion history, iron chelation, last pre-transfusion hemoglobin, and last serum ferritin levels).

Sample collection Five milliliter of blood samples were collected in two tubes (ethylenediaminetetraacetic acid and gel) at Fatimid foundation by a trained phlebotomist prior to blood transfusion to determine hemoglobin and serum ferritin.

Laboratory methodology Serum ferritin was measured by chemi-luminescent micro-particle immunoassay on Cobos® E-601 and hemoglobin was measured using Sysmex® XP-100.

Anthropometry World health organization (WHO) 2007 growth charts were used for boys and girls to assess their physical growth. Body mass index (BMI) was computed as weight in kg/height in square meters. z-Score of height (h-SDS), weight (w-SDS) and BMI. According to WHO reference 2007, a z-score of <−2 for height was considered as stunted growth and BMI of <−2 was considered as underweight or thin for age.

Statistical analysis Data were collected, managed, edited, entered, and analyzed by statistical package of social sciences (SPSS) version 22 and STATA 13 (Stata Corp, College Station, TX, U.S.A.). A descriptive analysis of all patients in the study was performed. In order to analyze the profile of the sample according to the variables studied, frequency tables for categorical variables like (gender, age group) were created. Male: female ratio was also computed. The mean ± standard deviation, minimum and maximum values were calculated for parametric and median and interquartile range (IQR; Q3-Q1) for non-parametric variables. Spearman rho correlation was used to test relationships between the non-parametric variables. The level of significance taken for all the statistical tests was a p-value of <0.05. The association of h-SDS with median serum ferritin levels was further confirmed by comparing these laboratory parameters in children with height z-scores <2 with those with the z-score ≥2 using the Mann-Whitney test.


Recruitment information / eligibility

Status Completed
Enrollment 367
Est. completion date December 31, 2014
Est. primary completion date December 31, 2014
Accepts healthy volunteers
Gender All
Age group 5 Years to 17 Years
Eligibility Inclusion Criteria:

- Children with transfusion dependent beta thalassemia major

- Age 5 to 17 years

- Subjects with informed consent

Exclusion Criteria:

- Age more than 17 years

- Subjects who refused informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
serum ferritin and hemoglobin test
Five milliliter of blood samples were collected in two tubes (ethylenediaminetetraacetic acid and gel) at Fatimid foundation by a trained phlebotomist prior to blood transfusion to determine hemoglobin and serum ferritin.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Aga Khan University

Outcome

Type Measure Description Time frame Safety issue
Primary Height in transfusion-dependent ß-thalassemia pediatric patients in Pakistan were recorded to assess growth rate Height in meters will be recorded from medical records of the patients Jan 2013 to Dec 2014
Primary Weight in transfusion-dependent ß-thalassemia pediatric patients in Pakistan were recorded to assess growth rate Wight in kilograms will be recorded from medical records of the patients Jan 2013 to Dec 2014
Primary Assessment of physical growth in transfusion-dependent ß-thalassemia pediatric patients in Pakistan were recorded to assess growth rate World health organization (WHO) 2007 growth charts were used for boys and girls to assess their physical growth. Body mass index (BMI) was computed as weight in kg/height in square meters (kg/m^2). z-Score of height (h-SDS), weight (w-SDS), and BMI (BMI-SDS) were also calculated. Jan 2013 to Dec 2014
Primary Serum ferritin levels and their association with z-Score of height Correlation was assessed between height for age z-score and serum ferritin levels. Serum ferritin was measured by chemi-luminescent micro-particle immunoassay on Cobos® E-601. The association of z-Score of height with median serum ferritin levels was further confirmed by comparing these laboratory parameters in children with height z-scores <2 with those with the z-score =2 using the Mann-Whitney test. Jan 2013 to Dec 2014
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03276455 - Gene Therapy for Beta-Thalassemia Major Using Autologous Hematopoietic Stem Cell Genetically Modified Phase 1/Phase 2
Completed NCT02674607 - the Potential Immunomodulatory Effects of Spirulina on Thalassemic Children N/A
Terminated NCT01571635 - Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia. Phase 2
Completed NCT04092205 - Phase 2a Pilot Study of NBMI Treatment in Patients With Beta Thalassemia Major, Requiring Iron Chelation Phase 2
Completed NCT02744560 - Effect of Spirulina on Liver Iron Concentration in Beta Thalassemic Children With Hepatitis C N/A
Recruiting NCT04353986 - PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders Phase 3
Not yet recruiting NCT02173951 - An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients Phase 2/Phase 3
Withdrawn NCT04776850 - Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies Early Phase 1
Completed NCT02744547 - Effect of Spirulina on Serum Hyaluronic Acid in Beta Thalassemic Children With Hepatitis C N/A
Completed NCT02744105 - Effect of Spirulina on Liver Fibrosis by Transient Elastography in Beta Thalassemic Children With Hepatitis C N/A
Active, not recruiting NCT03101423 - Monitoring of Chimerism After Transplantation in Patients With β Thalassemia Major and the Treatment Strategies for the Reduction of Chimerism N/A
Completed NCT02671695 - Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia N/A
Completed NCT00658385 - Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major N/A